Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Quesada

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
The Lancet. Oncology|April 11, 2022
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancerStanislas Quesada, William Jacot
Bulletin Du Cancer|October 25, 2024
[Fruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments]Chloé Chatelet, Stanislas Quesada
Bulletin Du Cancer|January 10, 2025
[The SFC in 2025, almost 120 years old and still full of new projects]Manuel Rodrigues, Stanislas Quesada
Bulletin Du Cancer|April 9, 2025
[Nivolumab plus ipilimumab in MSI metastatic colorectal cancers]Valentine Gangneux, Stanislas Quesada
Bulletin Du Cancer|January 8, 2022
[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)]Stanislas Quesada, Pauline Vaflard
Bulletin Du Cancer|September 13, 2023
[Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy]Tarik Rabehi, Stanislas Quesada
Annals of Translational Medicine|November 16, 2023
The quest for the optimal biomarker: is extending the spectrum of targeted <i>PIK3CA</i> mutations in breast cancer carcinoma worthwhile?Stanislas Quesada, William Jacot
Medecine Sciences : M/S|May 27, 2016
[Single cell next generation sequencing and characterization of new cell types]Stanislas Quesada, Philippe Jay
Bulletin Du Cancer|January 9, 2022
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10]Stanislas Quesada, Pauline Vaflard
Cancers|February 25, 2022
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesStanislas Quesada, Michel Fabbro, Jérôme Solassol
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|April 11, 2022
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancerStanislas Quesada, William Jacot
Bulletin Du Cancer|October 25, 2024
[Fruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments]Chloé Chatelet, Stanislas Quesada
Bulletin Du Cancer|January 10, 2025
[The SFC in 2025, almost 120 years old and still full of new projects]Manuel Rodrigues, Stanislas Quesada
Bulletin Du Cancer|April 9, 2025
[Nivolumab plus ipilimumab in MSI metastatic colorectal cancers]Valentine Gangneux, Stanislas Quesada
Bulletin Du Cancer|January 8, 2022
[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)]Stanislas Quesada, Pauline Vaflard
Bulletin Du Cancer|September 13, 2023
[Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy]Tarik Rabehi, Stanislas Quesada
Annals of Translational Medicine|November 16, 2023
The quest for the optimal biomarker: is extending the spectrum of targeted <i>PIK3CA</i> mutations in breast cancer carcinoma worthwhile?Stanislas Quesada, William Jacot
Medecine Sciences : M/S|May 27, 2016
[Single cell next generation sequencing and characterization of new cell types]Stanislas Quesada, Philippe Jay
Bulletin Du Cancer|January 9, 2022
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10]Stanislas Quesada, Pauline Vaflard
Cancers|February 25, 2022
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesStanislas Quesada, Michel Fabbro, Jérôme Solassol
Pageof 4